13263NVL-520-01OpenA Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)NCT05118789IndustryBothTreatmentI/IILung; ThyroidLiu, StephenGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterThoracic/CNS/H&N/ThyroidOncology GroupLombardi Comprehensive Cancer Center (LCCC)2021R3.1 Build 22 <a href="https://advarra.com" target="_blank">© 2024 Advarra, Inc.</a>